Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 112

1.

PROutine: a feasibility study assessing surveillance of electronic patient reported outcomes and adherence via smartphone app in advanced cancer.

Benze G, Nauck F, Alt-Epping B, Gianni G, Bauknecht T, Ettl J, Munte A, Kretzschmar L, Gaertner J.

Ann Palliat Med. 2019 Apr;8(2):104-111. doi: 10.21037/apm.2017.07.05. Epub 2017 Oct 26.

2.

Anaplastic pelvic carcinoma secondary to low-grade endometrial carcinoma.

Watrowski R, Möckel J, Venzke T, Jäger C, Bauknecht T.

Anticancer Res. 2014 Jan;34(1):239-42.

PMID:
24403469
3.

Randomized, phase II, placebo-controlled, double-blind study with and without enzastaurin in combination with paclitaxel and carboplatin as first-line treatment followed by maintenance treatment in advanced ovarian cancer.

Vergote IB, Chekerov R, Amant F, Harter P, Casado A, Emerich J, Bauknecht T, Mansouri K, Myrand SP, Nguyen TS, Shi P, Sehouli J.

J Clin Oncol. 2013 Sep 1;31(25):3127-32. doi: 10.1200/JCO.2012.44.9116. Epub 2013 Jul 29.

PMID:
23897968
4.

A randomized phase II non-comparative study of pemetrexed‑carboplatin and gemcitabine‑vinorelbine in anthracycline- and taxane-pretreated advanced breast cancer patients.

Amadori D, Carrasco E, Roesel S, Labianca R, Uziely B, Soldatenkova V, Moreau V, Desaiah D, Bauknecht T, Martin M.

Int J Oncol. 2013 May;42(5):1778-85. doi: 10.3892/ijo.2013.1869. Epub 2013 Mar 28.

PMID:
23546172
5.

Papillary-serous adenocarcinoma of the uterine cervix during tamoxifen therapy after bilateral breast cancer.

Watrowski R, Striepecke E, Jäger C, Bauknecht T, Horst C.

Anticancer Res. 2012 Nov;32(11):5075-8.

PMID:
23155282
6.

Taxane-based mono- or combination therapy for managing metastatic breast cancer (MBC) in routine practice: a multinational prospective observational study.

Gümüş M, Davidson N, Bauknecht T, Soldatenkova V, Benhadji KA.

Curr Med Res Opin. 2012 Mar;28(3):401-13. doi: 10.1185/03007995.2011.651795. Epub 2012 Jan 31.

PMID:
22181343
7.

A phase II trial of pemetrexed in combination with carboplatin in patients with recurrent ovarian or primary peritoneal cancer.

Sehouli J, Alvarez AM, Manouchehrpour S, Ghatage P, Szczylik C, Zimmermann A, Bauknecht T, Look KY, Oskay-Öezcelik G.

Gynecol Oncol. 2012 Feb;124(2):205-9. doi: 10.1016/j.ygyno.2011.09.007. Epub 2011 Nov 1.

PMID:
22044606
8.

A randomized phase II trial of doxorubicin plus pemetrexed followed by docetaxel versus doxorubicin plus cyclophosphamide followed by docetaxel as neoadjuvant treatment of early breast cancer.

Schneeweiss A, Marmé F, Ruiz A, Manikhas AG, Bottini A, Wolf M, Sinn HP, Mansouri K, Kennedy L, Bauknecht T.

Ann Oncol. 2011 Mar;22(3):609-17. doi: 10.1093/annonc/mdq400. Epub 2010 Aug 23.

PMID:
20732932
9.

A phase-I trial of pemetrexed plus carboplatin in recurrent ovarian cancer.

Sehouli J, Camara O, Mahner S, Bauknecht T, Lichtenegger W, Runnebaum I, Look K, Jaenicke F, Oskay-Oezcelik G.

Cancer Chemother Pharmacol. 2010 Oct;66(5):861-8. doi: 10.1007/s00280-009-1230-3. Epub 2010 Jan 7.

PMID:
20054549
10.

Carboplatin and paclitaxel in combination with oral enzastaurin in advanced ovarian or primary peritoneal cancer: results from a safety lead-in study.

Vergote I, Amant F, Oskay-Oezcelik G, Musib L, Michel AL, Darstein C, Kania M, Bauknecht T, Sehouli J.

Int J Gynecol Cancer. 2009 Dec;19(9):1505-10. doi: 10.1111/IGC.0b013e3181bda1a7.

PMID:
19955926
11.

Combination of enzastaurin and pemetrexed inhibits cell growth and induces apoptosis of chemoresistant ovarian cancer cells regulating extracellular signal-regulated kinase 1/2 phosphorylation.

Bräutigam K, Bauerschlag DO, Weigel MT, Biernath-Wüpping J, Bauknecht T, Arnold N, Maass N, Meinhold-Heerlein I.

Transl Oncol. 2009 Aug 18;2(3):164-73.

12.

The role of p53 as a surrogate marker for chemotherapeutical responsiveness in ovarian cancer.

Bauerschlag DO, Schem C, Weigel MT, Von Kaisenberg C, Strauss A, Bauknecht T, Maass N, Meinhold-Heerlein I.

J Cancer Res Clin Oncol. 2010 Jan;136(1):79-88. doi: 10.1007/s00432-009-0639-8.

PMID:
19609560
13.

Doxorubicin/pemetrexed followed by docetaxel versus doxorubicin/ cyclophosphamide followed by docetaxel as neoadjuvant treatment for early-stage breast cancer: a randomized phase II trial.

Schneeweiss A, Lauschner I, Ruiz A, Guerrero A, Sánchez-Rovira P, Seguí MA, Goerke K, Wolf M, Manikhas AG, Wacker J, Marmé F, Lichter P, Sinn HP, Sohn C, Mansouri K, Bauknecht T, Hahn M.

Clin Breast Cancer. 2007 Apr;7(7):555-8.

PMID:
17509164
14.

An integrated clinical-genomics approach identifies a candidate multi-analyte blood test for serous ovarian carcinoma.

Meinhold-Heerlein I, Bauerschlag D, Zhou Y, Sapinoso LM, Ching K, Frierson H Jr, Bräutigam K, Sehouli J, Stickeler E, Könsgen D, Hilpert F, von Kaisenberg CS, Pfisterer J, Bauknecht T, Jonat W, Arnold N, Hampton GM.

Clin Cancer Res. 2007 Jan 15;13(2 Pt 1):458-66.

15.

Molecular and prognostic distinction between serous ovarian carcinomas of varying grade and malignant potential.

Meinhold-Heerlein I, Bauerschlag D, Hilpert F, Dimitrov P, Sapinoso LM, Orlowska-Volk M, Bauknecht T, Park TW, Jonat W, Jacobsen A, Sehouli J, Luttges J, Krajewski M, Krajewski S, Reed JC, Arnold N, Hampton GM.

Oncogene. 2005 Feb 3;24(6):1053-65.

PMID:
15558012
16.

A randomized clinical trial of cisplatin/paclitaxel versus carboplatin/paclitaxel as first-line treatment of ovarian cancer.

du Bois A, Lück HJ, Meier W, Adams HP, Möbus V, Costa S, Bauknecht T, Richter B, Warm M, Schröder W, Olbricht S, Nitz U, Jackisch C, Emons G, Wagner U, Kuhn W, Pfisterer J; Arbeitsgemeinschaft Gynäkologische Onkologie Ovarian Cancer Study Group.

J Natl Cancer Inst. 2003 Sep 3;95(17):1320-9.

PMID:
12953086
17.

Gemcitabine combined with cisplatin as first-line treatment in patients 60 years or older with epithelial ovarian cancer: a phase II study.

Bauknecht T, Hefti A, Morack G, Villena-Heinsen C, Wallwiener D, Elling D, Minckwitz GV, Mansouri K, Blatter J, Breitbach GP.

Int J Gynecol Cancer. 2003 Mar-Apr;13(2):130-7.

PMID:
12657112
18.

Safety and immunogenicity of TA-HPV, a recombinant vaccinia virus expressing modified human papillomavirus (HPV)-16 and HPV-18 E6 and E7 genes, in women with progressive cervical cancer.

Kaufmann AM, Stern PL, Rankin EM, Sommer H, Nuessler V, Schneider A, Adams M, Onon TS, Bauknecht T, Wagner U, Kroon K, Hickling J, Boswell CM, Stacey SN, Kitchener HC, Gillard J, Wanders J, Roberts JS, Zwierzina H.

Clin Cancer Res. 2002 Dec;8(12):3676-85.

19.

Gene therapy of ovarian cancer.

Bauknecht T, Meinhold-Heerlein I.

Curr Womens Health Rep. 2002 Feb;2(1):39-46. Review.

PMID:
12112982
20.

Survey of genital lichen sclerosus in women and men.

Hagedorn M, Buxmeyer B, Schmitt Y, Bauknecht T.

Arch Gynecol Obstet. 2002 Apr;266(2):86-91.

PMID:
12049302
21.

Chemotherapy versus hormonal treatment in platinum- and paclitaxel-refractory ovarian cancer: a randomised trial of the German Arbeitsgemeinschaft Gynaekologische Onkologie (AGO) Study Group Ovarian Cancer.

du BA, Meier W, Lück HJ, Emon G, Moebus V, Schroeder W, Costa S, Bauknecht T, Olbricht S, Jackisch C, Richter B, Wagner U.

Ann Oncol. 2002 Feb;13(2):251-7.

PMID:
11886002
22.

Vaccination with autologous tumour antigen-pulsed dendritic cells in advanced gynaecological malignancies: clinical and immunological evaluation of a phase I trial.

Hernando JJ, Park TW, Kübler K, Offergeld R, Schlebusch H, Bauknecht T.

Cancer Immunol Immunother. 2002 Mar;51(1):45-52. Epub 2002 Jan 10.

PMID:
11845259
24.

Expression and potential role of Fas-associated phosphatase-1 in ovarian cancer.

Meinhold-Heerlein I, Stenner-Liewen F, Liewen H, Kitada S, Krajewska M, Krajewski S, Zapata JM, Monks A, Scudiero DA, Bauknecht T, Reed JC.

Am J Pathol. 2001 Apr;158(4):1335-44.

25.

Granulocyte colony-stimulating factor (G-CSF) receptor gene expression of ovarian carcinoma does not correlate with G-CSF caused cell proliferation.

Brandstetter T, Ninci E, Bettendorf H, Perewusnyk G, Stolte J, Herchenbach D, Sellin D, Wagner E, Köchli OR, Bauknecht T.

Cancer. 2001 Apr 1;91(7):1372-83.

PMID:
11283939
26.

Evaluation of methods to detect p53 mutations in ovarian cancer.

Meinhold-Heerlein I, Ninci E, Ikenberg H, Brandstetter T, Ihling C, Schwenk I, Straub A, Schmitt B, Bettendorf H, Iggo R, Bauknecht T.

Oncology. 2001;60(2):176-88.

PMID:
11244334
27.

G-CSF receptor expression in ovarian cancer.

Ninci EB, Brandstetter T, Meinhold-Heerlein I, Bettendorf H, Sellin D, Bauknecht T.

Int J Gynecol Cancer. 2000 Jan;10(1):19-26.

PMID:
11240647
28.

Cross-linked type I collagen C- and N-telopeptides in women with bone metastases from breast cancer.

Ulrich U, Rhiem K, Schmolling J, Flaskamp C, Paffenholz I, Sälzer H, Bauknecht T, Schlebusch H.

Arch Gynecol Obstet. 2001 Jan;264(4):186-90.

PMID:
11205705
29.

[Anthracyclines in therapy of ovarian carcinoma: a systematic review of primary and 2nd-line therapy after platinum].

du Bois A, Lück HJ, Pfisterer J, Meier W, Bauknecht T.

Zentralbl Gynakol. 2000;122(5):255-67. Review. German.

PMID:
10857212
30.

Detection of T helper responses, but not of human papillomavirus-specific cytotoxic T lymphocyte responses, after peptide vaccination of patients with cervical carcinoma.

Ressing ME, van Driel WJ, Brandt RM, Kenter GG, de Jong JH, Bauknecht T, Fleuren GJ, Hoogerhout P, Offringa R, Sette A, Celis E, Grey H, Trimbos BJ, Kast WM, Melief CJ.

J Immunother. 2000 Mar-Apr;23(2):255-66.

PMID:
10746552
31.

Vaccination with HPV16 peptides of patients with advanced cervical carcinoma: clinical evaluation of a phase I-II trial.

van Driel WJ, Ressing ME, Kenter GG, Brandt RM, Krul EJ, van Rossum AB, Schuuring E, Offringa R, Bauknecht T, Tamm-Hermelink A, van Dam PA, Fleuren GJ, Kast WM, Melief CJ, Trimbos JB.

Eur J Cancer. 1999 Jun;35(6):946-52.

PMID:
10533477
32.

Evaluation of neurotoxicity induced by paclitaxel second-line chemotherapy.

du Bois A, Schlaich M, Lück HJ, Mollenkopf A, Wechsel U, Rauchholz M, Bauknecht T, Meerpohl HG.

Support Care Cancer. 1999 Sep;7(5):354-61.

PMID:
10483822
33.

Phase II study of gemcitabine in ovarian cancer.

von Minckwitz G, Bauknecht T, Visseren-Grul CM, Neijt JP.

Ann Oncol. 1999 Jul;10(7):853-5.

PMID:
10470434
34.
35.

Response to IL-6 of HPV-18 cervical carcinoma cell lines.

Bauknecht T, Randelzhofer B, Schmitt B, Ban Z, Hernando JJ.

Virology. 1999 Jun 5;258(2):344-54.

36.

[Strategy and outcome of interdisciplinary therapy of ovarian carcinomas].

Ruf C, Kohlberger E, Bauknecht T, Farthmann EH.

Langenbecks Arch Chir Suppl Kongressbd. 1998;115:1494-6. German.

PMID:
9931922
37.

Localization of cytokeratin 10 mRNA in human epidermis using nonradioactive in situ hybridization as a routine method.

Meinhold-Heerlein I, Brandstetter T, Kommoss F, Bettendorf H, Hagedorn M, Bauknecht T.

Arch Dermatol Res. 1998 May;290(5):286-8. No abstract available.

PMID:
9681682
38.

Clinical phase I study with one-hour paclitaxel infusion.

Mross K, Hauns B, Häring B, Bauknecht T, Meerpohl HG, Unger C, Maier-Lenz H.

Ann Oncol. 1998 May;9(5):569-72.

PMID:
9653500
39.

rhG-CSF affects genes involved in mitogen signalling and early gene expression in the ovarian cancer cell line HEY.

Brandstetter T, Ninci E, Falken U, Wagner E, Hess R, Bauknecht T.

Int J Cancer. 1998 Mar 16;75(6):847-54.

41.

Phase I study of paclitaxel administered as a 1-hour infusion: toxicity and pharmacokinetics.

Maier-Lenz H, Hauns B, Haering B, Koetting J, Mross K, Unger C, Bauknecht T, du Bois A, Meerpohl HG, Hollaender N, Diergarten K.

Semin Oncol. 1997 Dec;24(6 Suppl 19):S19-16-S19-19.

PMID:
9427259
42.

Carboplatin/paclitaxel versus cisplatin/paclitaxel as first-line chemotherapy in advanced ovarian cancer: an interim analysis of a randomized phase III trial of the Arbeitsgemeinschaft Gynäkologische Onkologie Ovarian Cancer Study Group.

du Bois A, Lück HJ, Meier W, Möbus V, Costa S, Richter B, Warm M, Bauknecht T, Schröder W, Olbricht S, Nitz U, Jackisch C.

Semin Oncol. 1997 Oct;24(5 Suppl 15):S15-44-S15-52.

PMID:
9346222
43.

Carboplatin plus paclitaxel as first-line chemotherapy in previously untreated advanced ovarian cancer. German AGO Study Group Ovarian Cancer. Arbeitsgemeinschaft Gynäkologische Onkologie.

du Bois A, Lück HJ, Meier W, Möbus V, Costa S, Richter B, Bauknecht T, Warm M, Schroeder W, Olbricht S, Nitz U, Jackisch C.

Semin Oncol. 1997 Aug;24(4 Suppl 11):S11-28-S11-33.

PMID:
9314296
44.

UGP--a tumor marker of gynecologic and breast malignancies? Specificity and sensitivity in pretherapeutic patients and the influence of hormonal substitution on the expression of UGP.

Schwarz-Roeger U, Petzoldt B, Waldschmidt R, Walker RP, Bauknecht T, Kiechle M.

Anticancer Res. 1997 Jul-Aug;17(4B):3041-5.

PMID:
9329597
45.

Phase I/II study of the combination of carboplatin and paclitaxel as first-line chemotherapy in patients with advanced epithelial ovarian cancer.

du Bois A, Lück HJ, Bauknecht T, Möbus V, Bochtler H, Diergarten K, Meerpohl HG.

Ann Oncol. 1997 Apr;8(4):355-61.

PMID:
9209665
46.

Paclitaxel combined with carboplatin in the first-line treatment of advanced ovarian cancer: a phase I trial.

Meerpohl HG, du Bois A, Luck HJ, Kühnle H, Möbus V, Kreienberg R, Bauknecht T, Köchli O, Bochtler H, Diergarten K.

Semin Oncol. 1997 Feb;24(1 Suppl 2):S2-17-S2-22.

PMID:
9045330
48.

[Changes in serotonin metabolism in pre-eclampsia].

Schäfer CA, du Bois A, Vach W, Prömpeler H, Bauknecht T, Breckwoldt M.

Geburtshilfe Frauenheilkd. 1996 Aug;56(8):418-22. German.

PMID:
8974896
49.

Overrepresentation of 3q and 8q material and loss of 18q material are recurrent findings in advanced human ovarian cancer.

Arnold N, Hagele L, Walz L, Schempp W, Pfisterer J, Bauknecht T, Kiechle M.

Genes Chromosomes Cancer. 1996 May;16(1):46-54.

PMID:
9162197
50.

Increasing incidence of CD44v7/8 epitope expression during uterine cervical carcinogenesis.

Dall P, Hekele A, Ikenberg H, Göppinger A, Bauknecht T, Pfleiderer A, Moll J, Hofmann M, Ponta H, Herrlich P.

Int J Cancer. 1996 Apr 22;69(2):79-85.

Supplemental Content

Loading ...
Support Center